Esoterix Inc, Englewood, CO 80112, USA.
Am J Clin Pathol. 2013 Jan;139(1):102-9. doi: 10.1309/AJCPY6G6ZITVKPVH.
Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in antigen-based assays. The purpose of this study was to evaluate the effect of dabigatran on various specialized coagulation assays using normal plasma specimens with varying concentrations of dabigatran (the active form of dabigatran etexilate). We have demonstrated that samples containing therapeutic levels of dabigatran may lead to underestimation of intrinsic factor activities with abnormal activated partial thromboplastin time (aPTT) mixing study results and a false-positive factor VIII Bethesda titer; overestimation of protein C and protein S activity and activated protein C resistance ratio when determined using aPTT-based methods; and overestimation of results based on chromogenic anti-IIa assays but no effect on antigen assays and select chromogenic assays.
达比加群酯是一种新型的口服抗凝剂，作为直接凝血酶抑制剂发挥作用。凝血酶抑制剂有可能干扰所有基于血栓的凝固测定法和某些显色测定法，而药物预计不会干扰基于抗原的测定法。本研究的目的是评估达比加群对不同浓度达比加群（达比加群酯的活性形式）的正常血浆标本的各种特殊凝血测定法的影响。我们已经证明，含有治疗剂量达比加群的样本可能导致内在因子活性的低估，出现异常的活化部分凝血活酶时间（aPTT）混合研究结果和因子 VIII 贝塞斯达效价的假阳性；当使用基于 aPTT 的方法测定时，蛋白 C 和蛋白 S 活性及活化蛋白 C 抵抗比的高估；基于显色抗 IIa 测定法的结果高估，但对抗原测定法和某些显色测定法没有影响。
